Doctors Otto Yang and Harish Seethramraju used ler
Post# of 148277
(Total Views: 877)
Posted On: 10/06/2020 9:02:24 PM
Doctors Otto Yang and Harish Seethramraju used leronlimab on very sick patients:
"In mid-March 10 terminally ill COVID-19 patients were presented with a life or death choice by Dr. Seethramraju. Following treatment with Leronlimab, Dr. Seethramraju and Dr. Patterson observed rapid reduction in the cytokine inflammation storm in the patients. Of the 10 terminally ill patients, 5 survived.
Dr. Otto Yang, an infectious disease expert at the at UCLA, reported that 23 patients were injected with Leronlimab. Six were in critical condition , intubated on ventilators, 17 were severely ill requiring oxygen support. Of the 6 critical patients, three were extubated off ventilators, 2 patients remained relatively stable and still breathing and 1 patient had shown deterioration in respiratory parameters. Of the 17 severe cases, 11 patients demonstrated lung improvement, 8 were discharged from the hospital, 2 have shown lung deterioration. Information is pending for 2 recently treated patients. No deaths have been reported."
https://www.thisisthebronx.info/weekday-magaz...the-bronx/
More Dr. Otto Yang on how he used leronlimab on the EIND patients:
“We’re starting obviously with the most sick patients because they have the most to lose upfront,” he said.
https://www.nbclosangeles.com/news/coronaviru...d/2345620/
Based on the MOA, anecdotal data, and interviews with the doctors and patients involved, it's always been my impression that leronlimab has been observed as most effective in the Severe/Critical subpopulation.
What was the basis for you assertion that leronlimab works best for Moderate to Serious?
"In mid-March 10 terminally ill COVID-19 patients were presented with a life or death choice by Dr. Seethramraju. Following treatment with Leronlimab, Dr. Seethramraju and Dr. Patterson observed rapid reduction in the cytokine inflammation storm in the patients. Of the 10 terminally ill patients, 5 survived.
Dr. Otto Yang, an infectious disease expert at the at UCLA, reported that 23 patients were injected with Leronlimab. Six were in critical condition , intubated on ventilators, 17 were severely ill requiring oxygen support. Of the 6 critical patients, three were extubated off ventilators, 2 patients remained relatively stable and still breathing and 1 patient had shown deterioration in respiratory parameters. Of the 17 severe cases, 11 patients demonstrated lung improvement, 8 were discharged from the hospital, 2 have shown lung deterioration. Information is pending for 2 recently treated patients. No deaths have been reported."
https://www.thisisthebronx.info/weekday-magaz...the-bronx/
More Dr. Otto Yang on how he used leronlimab on the EIND patients:
“We’re starting obviously with the most sick patients because they have the most to lose upfront,” he said.
https://www.nbclosangeles.com/news/coronaviru...d/2345620/
Quote:
From all we know LL is most effective for Moderate, Moderate to Serious, and Serious conditions when vital organs are still mostly intact.
Based on the MOA, anecdotal data, and interviews with the doctors and patients involved, it's always been my impression that leronlimab has been observed as most effective in the Severe/Critical subpopulation.
What was the basis for you assertion that leronlimab works best for Moderate to Serious?
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼